Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
复制标题
重组癌胚抗原牛痘疫苗与白细胞介素 2 联合使用可改善免疫治疗。
作者：
J. P. McLaughlin;J. Schlom;J. Kantor;J. Greiner
白介素2(IL-2)是一种有效的免疫调节剂，在使用病毒或溶瘤疫苗的几种主动特异性免疫治疗实验方案中。在本报告中，有数据表明，在表达CEA的同基因实验小鼠模型系统中，IL-2的应用可以显著增强重组痘苗病毒-癌胚抗原(RV-CEA)疫苗单次免疫的治疗效果。对携带CEA阳性结肠癌的C57BL/6小鼠进行单次RV-CEA免疫，可使约20%的小鼠肿瘤完全消退。添加一个疗程的低剂量IL-2可使60%-70%的小鼠肿瘤完全消退。此外，RV-CEA和IL-2的结合可诱导系统免疫，从而保护那些无瘤小鼠免受表达CEA的肿瘤细胞的再次攻击。在那些单独使用野生型牛痘疫苗(V-Wyeth)或单独注射IL-2的小鼠中，没有观察到这样的肿瘤消退或保护作用。细胞免疫分析显示，与单独接种RV-CEA相比，在RV-CEA免疫中加入IL-2可显著提高CEA特异性T细胞增殖反应和细胞溶解T细胞反应。CEA特异性免疫反应的增强，加上IL-2治疗后实验治疗结果的改善，表明在针对CEA表达肿瘤的主动特异性免疫治疗临床方案中，使用该细胞因子治疗可能有效地替代多次RV-CEA免疫。
Interleukin-2 (IL-2) has been an effective immune modulator in several active-specific immunotherapy experimental protocols using either viral or oncolysate-based vaccines. In this report, data indicate that IL-2 administration can appreciably augment the therapeutic effect of a single immunization of a recombinant vaccinia virus-carcinoembryonic antigen (rV-CEA) vaccine using a CEA-expressing syngeneic experimental murine model system. A single rV-CEA immunization of C57BL/6 mice bearing palpable CEA-positive colon adenocarcinoma tumors results in complete tumor regression in approximately 20% of the mice. The addition of a course of low-dose IL-2 results in complete tumor regression in 60-70% of the mice. Moreover, the combination of rV-CEA and IL-2 induces systemic immunity, which protects those tumor-free mice from subsequent rechallenge with the CEA-expressing tumor cells. No such tumor regression or protection was observed in those mice immunized with the wild-type vaccinia vaccine (V-Wyeth) alone or with IL-2 administration alone. Cellular immune assays revealed that the addition of IL-2 to rV-CEA immunization significantly increased the CEA-specific T-cell proliferative responses as well as the cytolytic T-cell responses when compared with rV-CEA immunization alone. The enhanced CEA-specific immune response, coupled with the improved experimental therapeutic outcome following IL-2 administration, suggests that treatment with that cytokine may effectively substitute for multiple rV-CEA immunizations in active-specific immunotherapy clinical protocols directed at CEA-expressing tumors.
疫苗引发的T淋巴细胞体外对肿瘤继发敏化的过继免疫治疗的临床观察。
影响因子：
11.2
作者：
Chang,AE;Yoshizawa,H;Sakai,K;Cameron,MJ;Sondak,VK;Shu,S
通讯作者：
Shu,S
B7-1 表达导致差异化 T 细胞激活。
影响因子：
6.4
作者：
Li,Wei;Rosenzweig,Anthony;Huber,BrigitteT
通讯作者：
Huber,BrigitteT
IL-2的体内给药。
DOI：
10.1007/978-1-4684-4838-2_11
发表时间：
1985
期刊：
Contemporary topics in molecular immunology
影响因子：
--
作者：
Cheever,MA;Greenberg,PD
通讯作者：
Greenberg,PD